Medtronic plc (MDT) has shared late-breaking clinical trial results for its PulseSelect Pulsed Field Ablation (“PFA”) system, demonstrating a high rate of durable lesion formation in treating atrial fibrillation (Afib). The findings were presented at the Asia Pacific Heart Rhythm Society meeting held in Sydney, Australia.The widespread adoption of PulseSelect also continues, with more than 10,000 cases having been performed worldwide.Predicting MDT Stock Movement Following the NewsAfter the announcement, Me ...

APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopySuccessful launch in Japan follows recent reimbursement approval  Approvals across APAC including China and Australia broaden reach for patientsGALWAY, Ireland and SYDNEY, Sept. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSe ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Core Insights - Federated Hermes, Inc. has launched the Federated Hermes MDT Mid Cap Growth Collective Investment Fund aimed at qualified retirement plan investors, focusing on capital appreciation through a diversified portfolio of US mid-cap growth companies [1][2] - The fund utilizes a systematic, bottom-up stock-selection process that leverages advanced research and technology to minimize subjective influences [1][2] - The fund is managed by an experienced team with a combined total of over 81 years in investment management, overseeing more than $10 billion in various investment vehicles [2][3] Company Overview - Federated Hermes is a global leader in active investment management, with $782.7 billion in assets under management as of June 30, 2024, serving over 10,000 institutions and intermediaries worldwide [4] - The company offers a wide range of investment solutions, including equity, fixed-income, alternative/private markets, multi-asset, and liquidity management strategies [4] - Federated Hermes has a significant presence with more than 2,000 employees across various global offices, including locations in London, New York, and Boston [4] Fund Details - The new MDT Mid Cap Growth fund is Federated Hermes' first equity collective investment trust (CIT), complementing existing fixed-income CITs [3] - The fund aims to differentiate itself by seeking alpha from multiple sources, enhancing its appeal in the retirement market [2] - The management team includes Daniel Mahr, CFA, Damien Zhang, CFA, Frederick Konopka, CFA, and John Paul Lewicke, each bringing extensive experience to the fund's operations [2]

At the North American Spine Society's 39th Annual Meeting in Chicago, Medtronic plc (MDT) commercially launched several software, hardware and imaging innovations to advance its AiBLE spine technology ecosystem. In addition, the company announced a partnership with Siemens Healthineers to explore opportunities for expanding access to cutting-edge pre and post-operative imaging technologies for spine care. MDT Stock's Trend Following the News After the announcement, shares of MDT dipped 0.4% to close at $89. ...

GALWAY, Ireland and CHICAGO, Sept. 25, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations. These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cra ...

A month has gone by since the last earnings report for Medtronic (MDT) . Shares have added about 0.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Medtronic Q1 Earnings, Revenues Top Estimates, Margins D ...

CottonCandyClouds/iStock via Getty Images Medtronic PLC (NYSE:MDT) is a global developer and manufacturer of medical devices for chronic diseases. Founded in 1949, Medtronic is now a $111 billion (by market cap) healthcare behemoth that employs 95,000 people. The company reports results across four segments: Cardiovascular, 37% of FY 2023 revenue; Neuroscience, 29%; Medical Surgical, 27%; and Diabetes, 7%. Medtronic's product portfolio is comprised of a variety of life-saving and life-improving medical devi ...

Group 1: Dividend Stocks Overview - Dividend income can enhance portfolio growth and provide flexibility in usage [1] - Investing in dividend stocks is a strategy to navigate market volatility [1] Group 2: Medtronic (MDT) - Medtronic is a leading global manufacturer of medical devices, with a strong history of dividend payments, increasing dividends for 46 consecutive years [3][4] - The company currently pays out approximately 93% of its earnings as dividends, with a forward annual dividend rate of $2.80 per share, yielding about 3% [3] - In the last 12 months, Medtronic reported profits of around $4 billion on revenues of approximately $33 billion, with operating cash flow nearing $7 billion [3] - The most recent quarter showed a modest 3% year-over-year revenue growth, but net profit surged by 32% to just over $1 billion, driven by growth in cardiovascular and diabetes product portfolios [4] - Medtronic's stock price performance has been moderate, presenting a potential buying opportunity with a price-to-sales (P/S) ratio of less than 4 [5] Group 3: Target (TGT) - Target has a strong dividend history, with its upcoming Q3 dividend marking the 228th consecutive payment since 1967 and on track for its 53rd consecutive year of dividend increases [6] - The company yields approximately 3% based on current share prices, with a forward annual dividend of $4.48 per share, paying out 46% of its earnings in dividends [6] - Target faced challenges post-pandemic, including changing consumer shopping patterns and excess inventory, which impacted growth and profitability [7] - Recent financial reports indicate a recovery, with total revenue of around $26 billion, up 2.7% year-over-year, and digital sales growing by 8.7% [8] - Target's operating income rose by 36.6% to $1.6 billion, and net earnings increased by 43% to $1.2 billion year-over-year, indicating solid performance for income investors [9]

The past month has been quite encouraging for Medtronic (MDT) investors. Solid first-quarter fiscal 2025 organic growth performance and several strategic initiatives to revamp the bottom line, including the COGS cost-out programs, while maintaining pricing and maximizing efficiencies, seem to have boosted market sentiment.Added to this, growing optimism surrounding the Fed’s approach toward an imminent rate cut in September acts as a strong impetus in driving the stock price. All these have nullified the on ...